LP
AKRO

LMR Partners’s Akero Therapeutics AKRO Stock Holding History

LMR Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$758K – 1099
2024
Q1 		$758K Buy
+30,000
New +$721K 0.01% 714
2023
Q4 		– Sell
-82,400
Closed -$4.17M – 982
2023
Q3 		$4.17M Buy
+82,400
New +$3.84M 0.05% 280

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LMR Partners's AKRO Position: Q4 2024 in Review

LMR Partners sold out of Akero Therapeutics (AKRO) in Q4 2024, closing a stake of 20,597 shares — an estimated $624K sold.

LMR Partners first reported a position in AKRO in Q1 2024 and held it in 3 quarters. The position peaked at $591K in Q3 2024. 191 funds tracked by Wall St. Rank hold AKRO as of Q4 2024.

  • LMR Partners reported no remaining Akero Therapeutics position as of Q4 2024 after selling out during the quarter.
  • LMR Partners sold 20,597 Akero Therapeutics shares in Q4 2024, an estimated $624K.
  • LMR Partners first reported a position in Akero Therapeutics in Q1 2024 and held it in 3 quarters.
  • LMR Partners's Akero Therapeutics position peaked at $591K in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2024.

Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.